Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mayocp.2015.01.019 http://scihub22266oqcxt.onion/10.1016/j.mayocp.2015.01.019 C4404467!4404467 !25841258     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25841258 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25841258 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Mayo+Clin+Proc 2015 ; 90 (4 ): 546-54 Nephropedia Template TP {{tp|p=25841258 |t=2015. Regenerative medicine in diabetes |pdf=|usr=}}{{25841258 }} gab.com Text Regenerative medicine in diabetes JO: Mayo Clin Proc http://www.kidney.de/pget.php?&tw=1&pmid=25841258 #FOAvip Diabetes is a common multisystem disease that results in hyperglycemia due to a relative or absolute insulin deficiency. Improved glycemic control decreases the risk of development and progression of microvascular and, to a lesser extent, macrovascular complications and prevents symptomatic hyperglycemia. However, complex treatment regimens aimed at improving glycemic control are associated with an increased incidence of hypoglycemia. On paper at least, cellular therapies arising from reprogramed stem cells or other somatic cell types would provide ideal therapy for diabetes and the prevention of its complications. This hypothesis has led to intensive efforts to grow ? cells from various sources. In this review, we provide an overview of ?-cell development as well as the efforts reported to date in terms of cellular therapy for diabetes. Engineering ?-cell replacement therapy requires an understanding of how ? cells respond to other metabolites such as amino acids, free fatty acids, and ketones. Indeed, efforts thus far have been characterized by an inability of cellular replacement products to adequately respond to metabolites that normally couple the metabolic state to ?-cell function and insulin secretion. Efforts to date intended to capitalize on current knowledge of islet cell development and stimulus-secretion coupling of the ? cell are encouraging but as yet of little clinical relevance. Twit Text FOAVip Regenerative medicine in diabetes ????Mayo Clin Proc http://www.kidney.de/pget.php?&tw=1&pmid=25841258 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25841258 #FOAvip English Wikipedia <ref>{{Cite pmid|25841258 }}</ref> Regenerative medicine in diabetes #MMPMID25841258 Matveyenko A ; Vella A Mayo Clin Proc 2015[Apr]; 90 (4 ): 546-54 PMID25841258 show ga Diabetes is a common multisystem disease that results in hyperglycemia due to a relative or absolute insulin deficiency. Improved glycemic control decreases the risk of development and progression of microvascular and, to a lesser extent, macrovascular complications and prevents symptomatic hyperglycemia. However, complex treatment regimens aimed at improving glycemic control are associated with an increased incidence of hypoglycemia. On paper at least, cellular therapies arising from reprogramed stem cells or other somatic cell types would provide ideal therapy for diabetes and the prevention of its complications. This hypothesis has led to intensive efforts to grow ? cells from various sources. In this review, we provide an overview of ?-cell development as well as the efforts reported to date in terms of cellular therapy for diabetes. Engineering ?-cell replacement therapy requires an understanding of how ? cells respond to other metabolites such as amino acids, free fatty acids, and ketones. Indeed, efforts thus far have been characterized by an inability of cellular replacement products to adequately respond to metabolites that normally couple the metabolic state to ?-cell function and insulin secretion. Efforts to date intended to capitalize on current knowledge of islet cell development and stimulus-secretion coupling of the ? cell are encouraging but as yet of little clinical relevance. |*Cell Engineering [MESH] |*Regenerative Medicine [MESH] |Diabetes Mellitus/etiology/pathology/*therapy [MESH] |Humans [MESH]Regenerative medicine in diabetes (epmc).pdf DeepDyve Pubget Overpricing